VYNE | VYNE Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.7100 - 2.8900
52 Week Range	1.5700 - 4.09
Beta	1.79
Implied Volatility	522.43%
IV Rank	51.15%
Day's Volume	57,666
Average Volume	74,326
Shares Outstanding	14,751,400
Market Cap	41,598,948
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-01-25

Valuation
Profitability
Growth
Health
P/E Ratio	0.85
Forward P/E Ratio	N/A
EPS	3.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	USA
Website	VYNE

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE's peers: AKTX, SLRX, AXLA, MGTA, HSTO, FWBI, SABS, VCNX, GOVX, CBIO, UNCY, PULM, CDTX, PHIO, KRON, VCYT, BCEL, LGVN, LYRA, REVB, ZURA, ZVSA, RNAZ

*Chart delayed

Analyzing fundamentals for VYNE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see VYNE Fundamentals page.

Watching at VYNE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VYNE Technicals page.